

ASX RELEASE



ASX Code: ESE

13 February 2018

ESENSE WINS COURT PROCEEDINGS

Life sciences company **eSense-Lab Ltd** (“**eSense**” or the “**Company**”) (ASX: ESE) is pleased to announce that proceedings commenced in Israel by two Directors of the Company on 11 February 2018, against the Company and remaining Directors, have been dismissed.

As announced on 9 February 2018, the board of Directors (“**Board**”) resolved at its meeting on 8 February 2018 to, amongst other things, appoint Mr Ilan Saad as Chairman of the Board (replacing Dr Brendan de Kauwe), to cancel the annual general meeting (“**AGM**”) scheduled for 15 February 2018, and to convene the AGM together with the extraordinary general meeting (“**EGM**”) requisitioned by certain securityholders of the Company for 29 March 2018.

On 11 February 2018, two Directors, Dr Brendan de Kauwe and Mr Quentin Megson, commenced proceedings in Israel against the Company and the remaining Directors, seeking a number of remedies including the cancellation of the resolution replacing Dr Brendan de Kauwe as Chairman, the cancellation of the AGM scheduled for 29 March 2018 and an order relating to the previously scheduled AGM.

In an urgent Court hearing held in Lod, Israel on 12 February 2018, the Court rejected all of the motions brought by Dr de Kauwe and Mr Megson. In doing so, the Court found that the Board acted properly in passing the resolutions it passed on 8 February 2018, and ruled that the Company’s AGM and EGM are to be held on 29 March 2018 (with any further changes to the date of the meeting requiring Court approval).

The Company remains committed to holding AGM and EGM on 29 March 2018. As per the Company’s announcement of 9 February 2018, the Notice of Meeting and voting instructions for these meetings will be provided to all securityholders, and to the ASX, in due course.

FOR FURTHER INFORMATION:

Haim Cohen
CEO & Director
haim@esense-lab.com

[Investor/media relations](#)
Matthew Wright
+61 451 896 420
matt@nwrcommunications.com.au

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to ‘reverse engineer’ a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant’s health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.

To learn more about eSense-Lab, visit www.esense-lab.com